Chemistry:Brimarafenib
From HandWiki
Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.[1][2]
It is being developed by MapKure, LLC, a joint venture between SpringWorks Therapeutics and BeiGene.[1]
References
- ↑ 1.0 1.1 "Brimarafenib". https://synapse.patsnap.com/drug/c1fe90a4872b4cf7be750bd04ddb19ed.
- ↑ "Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma". SSRN. doi:10.2139/ssrn.4934723.
 |  |
